RE: RNS11 Feb 2026 12:24
I'm happy to take them at their word ... ie .. to generate non-dilutive funding
Genflow Biosciences PLC - London-based biotechnology firm - Says 2026 will "emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest." Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding "With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies."